Genomic profiling and outcomes of cancers in World Trade Center-exposed survivors and responders
Official title: Genomic Characterization and Clinical Outcomes of Cancers in WTC-Exposed Survivors & Responders
Funded at Sloan-Kettering Inst Can Research · NIH-11578869 · Data updated 2026-11-12
This project looks at the genetic makeup and real-world cancer outcomes in people exposed to the World Trade Center disaster to understand how their cancers behave and respond to treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $287,197 |
| NIH project number | 1R21OH013130-01 |
| Project ID | NIH-11578869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with cancer who are or were World Trade Center-exposed survivors or responders, with available tumor sequencing or tissue for profiling.
✕Less likely to help
Patients without access to sequencing data or with cancers not driven by genomic alterations may have limited direct benefit.
What this research studies
Researchers will analyze tumor genetics and clinical data from thousands of World Trade Center-exposed cancer patients to map somatic changes and link them with treatment responses. Using the MSK-IMPACT sequencing data and clinical records, the team aims to build a clinicogenomic picture that could guide personalized cancer care for this population. The study will integrate genomic findings with patient outcomes to identify actionable mutations and potential targeted therapies. By focusing on a specific disaster-exposed cohort, the work seeks to inform care strategies and improve survival and quality of life for affected individuals.
Why it matters
Potential benefit: Patients could see more tailored treatment options based on their tumor genetics and exposure history.
How similar studies have gone: Previous multi-cancer clinicogenomic efforts have shown that linking genetics with outcomes can highlight actionable targets and inform care.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Schultz, Nikolaus — Sloan-Kettering Inst Can Research
- Study coordinator: Schultz, Nikolaus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.